Syndax Pharmaceuticals, Inc. SNDX
14.29 USD +1.19 (+9.08%)
At closeNov 3, 2026, 4:00 PM EST
14.29 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
13.07 Day range 14.49
12.80 52-week range 25.59
- YTD
- -31.98%
- 1 year
- +3.85%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.27 +160.8% upside
Now 14.29
- Target (low)
- 23.00
- Target (mean)
- 37.27
- Target (high)
- 57.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy2
- Buy10
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 12
- 3 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.48378 | -0.53419 – -0.375 | -0.78 | +38.0% | 96.20M | +40.0% | 11 |
| Current year | -1.91 | -2.24 – -1.35 | -3.29 | +42.0% | 316.16M | +83.4% | 10 |
| Next year | -0.7254 | -1.96 – 0.39865 | -1.91 | +62.0% | 460.12M | +45.5% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 21, 2026 | UBS | Maintained | Buy | Buy |
| Aug 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 12, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 22, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2026 | UBS | Maintained | Buy | Buy |
| May 1, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 1, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 31, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 9, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 2, 2026 | Citigroup | Maintained | Buy | Buy |
| Dec 9, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 24, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 12, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 4, 2025 | UBS | Maintained | Buy | Buy |
| Nov 4, 2025 | Barclays | Maintained | Overweight | Overweight |
| Oct 27, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 27, 2025 | BTIG | Reiterated | Buy | Buy |
| Sep 19, 2025 | BTIG | Reiterated | Buy | Buy |
| Sep 5, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Sep 4, 2025 | Guggenheim | Initiated | — | Buy |
| Aug 5, 2025 | Citigroup | Maintained | Buy | Buy |
| Aug 5, 2025 | BTIG | Maintained | Buy | Buy |
| Jul 15, 2025 | UBS | Maintained | Buy | Buy |
| Jul 10, 2025 | Goldman Sachs | Initiated | — | Buy |
| May 6, 2025 | Scotiabank | Maintained | Sector Perform | Sector Perform |
| May 6, 2025 | Guggenheim | Reiterated | Buy | Buy |